WST

AI Research

CEO retirement announced → 2026 guidance reaffirmed at 5%-7% organic growth; $1B buyback

West Pharmaceutical Services announced CEO Eric Green's retirement while reaffirming 2026 targets of $3.215-$3.275B net sales (5-7% organic growth) and adjusted EPS of $7.85-$8.20. The board authorized a new $1.0 billion share repurchase program with no expiration date, signaling confidence in cash flow generation. FY2025 net sales totaled $3.07B (+6.3%) with full-year adjusted diluted EPS of $7.29 (+8.0%).